Skip to content
Clinical Trials – home
Not recruiting

Study of LY3871801 for Adults with Moderate to Severe Rheumatoid Arthritis

Verified siteFast replyInvestigational
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the effects of a new treatment for Rheumatoid Arthritis, a condition that causes pain and swelling in the joints. The treatment being tested is a medication called LY3871801, which is taken in the form of a tablet. The study will compare the effects of LY3871801 to a placebo, which looks like the medication but does not contain the active ingredient.

The purpose of the study is to evaluate how well LY3871801 works in reducing the symptoms of rheumatoid arthritis. Participants in the study will be randomly assigned to receive either LY3871801 or a placebo. The study is designed to be "double-blind," meaning neither the participants nor the researchers will know who is receiving the actual medication and who is receiving the placebo. This helps ensure that the results are not influenced by expectations about the treatment.

The study will take place over a period of up to 24 weeks. During this time, participants will have regular check-ups to monitor their health and the effects of the treatment. The main goal is to see if LY3871801 can help reduce the activity of the disease, as measured by specific health indicators. Participants will be closely monitored to ensure their safety throughout the study.

The research process

The trial runs in 4 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, you will be randomly assigned to receive either the study medication, LY3871801, or a placebo. A placebo is a tablet that looks like the study medication but does not contain the active ingredient.

  2. Step 2

    Medication administration

    You will take the assigned tablet orally. The dosage is 25g of LY3871801 or the matching placebo. The frequency and duration of administration will be explained to you by the study team.

  3. Step 3

    Monitoring and assessments

    Throughout the study, your health and the effects of the medication will be monitored. This includes regular assessments of your rheumatoid arthritis symptoms.

    The main goal in Phase 2a is to observe changes in your disease activity score, which is a measure of your rheumatoid arthritis symptoms.

    In Phase 2b, the focus is on the percentage of participants achieving a significant improvement in symptoms, known as ACR50.

  4. Step 4

    End of study

    The study is expected to conclude by July 15, 2026. At the end of the study, you will have a final assessment to evaluate the overall effects of the treatment.

Who can join the trial?

3 criteria

  • Must have a diagnosis of rheumatoid arthritis for at least 3 months. Rheumatoid arthritis is a condition that causes pain and swelling in the joints.
  • Must be an adult. This means you need to be at least 18 years old.
  • Both men and women can participate in the study.

Who cannot join the trial?

10 criteria

  • Patients with any other serious health conditions that could interfere with the study.
  • Patients who are pregnant or breastfeeding.
  • Patients who have participated in another clinical trial within the last 30 days.
  • Patients with a history of allergic reactions to similar medications.
  • Patients who are unable to follow the study procedures or attend scheduled visits.
  • Patients with active infections that require treatment.
  • Patients with a history of drug or alcohol abuse.
  • Patients who have received certain medications that might interfere with the study drug.
  • Patients with a history of cancer, except for certain types of skin cancer.
  • Patients with uncontrolled high blood pressure or diabetes.
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

LY3871801 is a new medication being tested to see if it can help people with rheumatoid arthritis, which is a condition that causes pain and swelling in the joints. The study is looking at how well this medication works in reducing the symptoms of rheumatoid arthritis compared to not taking the medication. The goal is to see if people feel better and have less joint pain and swelling when they take LY3871801. This medication is still being studied, so it is not yet available for general use. The trial is designed to find out if LY3871801 can be a safe and effective treatment option for people with this condition.

What is already known about the treatment

LY3871801 – LY3871801 is a medication currently being studied for its potential to treat moderately-to-severely active rheumatoid arthritis. It is administered in a form that is not specified in the available data, but it is being compared to a placebo in clinical trials. The main goal of the study is to see how well LY3871801 can reduce symptoms of rheumatoid arthritis, which is a condition that causes pain and swelling in the joints. The medication works at the molecular level by targeting specific pathways involved in inflammation, although the exact mechanism is not detailed in the provided information. LY3871801 is classified under pharmacological agents that aim to reduce inflammation and improve joint function.

Investigated diseases

Rheumatoid Arthritis – Rheumatoid Arthritis is a chronic inflammatory disorder that primarily affects the joints. It typically begins with inflammation in the small joints of the hands and feet, leading to swelling, pain, and stiffness. Over time, the inflammation can cause joint damage and deformities. The disease may progress to affect larger joints, such as the knees, hips, and shoulders. In some cases, it can also impact other body systems, including the skin, eyes, lungs, and blood vessels. The progression of the disease varies among individuals, with periods of increased activity, known as flares, and times of remission.
Trial detailsLast updated 18 Nov 2026
Age18+ yearsPhasePhase IITrial ID2022-502994-40-00Estimated enrolment332 patientsSponsorEli Lilly & Co.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.